Navigation Links
PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Date:9/30/2008

r human health needs."

"An alliance with PharmAthene presents important strategic opportunities to create value for both of our companies," said Mr. Rajesh Jain, Joint Managing Director of Panacea Biotec. "Panacea Biotec is committed to identifying partners for US distribution of our products. We recognize PharmAthene's strength in the biodefense space and the core competencies of its management team with respect to vaccine development and commercialization. We are very pleased to participate in this strategic alliance."

Under a related agreement, PharmAthene has the first right of negotiation for US distribution of certain of Panacea Biotec's biodefense products and may enter into discussions with Panacea Biotec regarding potential strategic collaborations that could include development and manufacturing by Panacea Biotec of certain PharmAthene biodefense products.

The investment will increase PharmAthene's ongoing product development activities, enhance working capital, and provide new resources for corporate growth. Immediately after the closing Panacea Biotec, through its subsidiary, will own approximately 14.5% of PharmAthene's issued and outstanding common stock and, with the warrant, will have the right to purchase up to an additional 2.75 million shares, subject to a stock ownership cap, following any warrant exercise, of 19.99% of PharmAthene's issued and outstanding common stock. During the next three years Panacea Biotec has agreed not to purchase additional shares of PharmAthene stock without the prior written consent of PharmAthene. Panacea Biotec's subsidiary will be granted limited rights to participate in future private financings by PharmAthene to maintain its then current ownership level. In addition, PharmAthene will retain full rights to its proprietary information and technology and full management and operational control.

About the Securities

The securities that are being sold in the transaction have not been
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... Grenoble, France and Dallas, TX, USA (PRWEB) , ... ... ... manufacturer of innovative nano and microsystems, has appointed Francois Vieillard as Sales & ... & Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... for Biologically Inspired Engineering at Harvard University have developed ... seek out specific cell targets within a complex mixture ... as telling cancer cells to self-destruct. Inspired by the ... might one day be used to program immune responses ...
... ORLANDO, Fla., Feb. 16, 2012   GeneLink ... biotech company, has completed the sale of the ... Life Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: ... and wellness marketplace.  As previously disclosed, GeneLink and ...
... -- FirstMark today announced the completion of the clinical ... These clinical results demonstrate the extraordinary effectiveness of the ... myocardial infarction and death in patients with suspected or ... final data was well received in an oral presentation, ...
Cached Biology Technology:Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 2Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 3GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2FirstMark's Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI 2
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... July 7, 2015  Based on its recent ... Sullivan recognizes Credence ID, LLC with the 2015 ... of the Year Award. Credence ID has developed ... its mission of offering enrollment and identification solutions ... Credence ID was formed by experts from the ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... one way to get children to eat more whole grains, ... Federal nutrition guidelines recommend at least three servings a day ... typically only eat about one serving per day, largely because ... In this study, researchers served graham snacks with four ...
... EAST LANSING, Mich. A Michigan State University researcher ... parkin may help nerve cells fight off damage from ... therapies for the degenerative ailment. John Goudreau, an ... Unit, believes parkin can rescue certain neurons from injury ...
... programmed cell death, is essential to normal development, ... process dramatically transforms cellular structures but the limitations ... this structural reorganization a mystery. , Now, in ... issue of Proceedings of the National Academy ...
Cached Biology News:Specific protein may help neurons fix themselves in Parkinson's patients 2How do cells die? Biophotonic tools reveal real-time dynamics in living color 2How do cells die? Biophotonic tools reveal real-time dynamics in living color 3
XEDAR Antibody...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
...
...
Biology Products: